Clinical Trial Cost Estimation: Key Drivers and Budgeting

Clinical trial costs vary widely based on therapeutic area, phase, protocol complexity, and site count. A Phase 1 study conducted at a US site can cost from US$1.4 million in pain and anesthesia to US$6.6 million in immunomodulation, while Phase 3 studies range from US$11.5 million in dermatology to US$52.9 million in pain and anesthesia. Understanding these drivers before protocol finalization allows sponsors and investigators to build realistic budgets, allocate contingency funds, and avoid common planning failures.

This article provides an evidence-based framework for estimating clinical trial costs and constructing a budget template. It draws on published analyses of cost drivers, health economics methodology, and regulatory guidance documents. The intended readers are clinical research professionals, academic investigators, life-science students, and informed general readers who need a practical approach to trial budgeting.

At a Glance: Clinical Trial Cost Drivers and Budgeting Framework

The Clinical Trial Lifecycle and Where Costs Accumulate

The clinical trial lifecycle spans protocol design, regulatory submission, site selection and activation, patient recruitment and enrollment, treatment and follow-up, data collection and monitoring, analysis, and reporting. Costs accumulate at every stage, but the distribution is uneven. Clinical procedure costs represent 15% to 22% of total expenditures across all phases when site overhead and sponsor monitoring costs are excluded, according to a study of aggregate data from three proprietary databases on clinical trial costs provided by Medidata Solutions [7]. Administrative staff and patient recruitment also rank among the top cost drivers [7].

The same study found that therapeutic area is an important determinant of clinical trial costs by phase [7]. This means that a budget built for an oncology trial cannot be transferred to a dermatology trial without substantial revision. The protocol design decisions that drive procedure counts, visit schedules, and laboratory testing requirements have direct financial consequences.

Budget planning should begin during protocol development, not after the protocol is finalized. Changes to inclusion criteria, endpoint definitions, or visit frequency after the budget is set can create unbudgeted expenses. The cost calculation template developed by a working group within the pan-European paediatric study network c4c/GermanNetPaeT illustrates how detailed time estimates for each measure and investigation can support internal cost calculation and preparation of financing requirements for sponsors or public funders [10]. The same logic applies across therapeutic areas.

Key Cost Drivers by Phase and Therapeutic Area

Phase 1 Study Costs

Phase 1 studies are typically the first human exposure to a new compound and focus on safety, tolerability, and pharmacokinetics. The average cost of a Phase 1 study conducted at a US site ranged from US$1.4 million in pain and anesthesia to US$6.6 million in immunomodulation, including estimated site overhead and monitoring costs of the sponsoring organization [7]. The wide range reflects differences in the number of cohorts, the intensity of safety monitoring, and the complexity of the procedures required.

Phase 1 budgets should account for the cost of healthy volunteer recruitment, inpatient or outpatient confinement periods, intensive pharmacokinetic sampling, and repeated safety assessments. Immunomodulation studies tend to be more expensive because of the need for specialized immunogenicity assays and longer follow-up periods.

Phase 2 Study Costs

Phase 2 studies evaluate efficacy and further characterize safety in a patient population. A Phase 2 study cost from US$7.0 million in cardiovascular disease to US$19.6 million in hematology on average [7]. The increase over Phase 1 reflects larger sample sizes, multiple dose groups, and the use of disease-specific efficacy endpoints.

Hematology trials are expensive because of the cost of blood product support, specialized laboratory testing, and the complexity of managing patients with hematologic disorders. Cardiovascular trials may be less expensive per study if they use relatively simple endpoints and shorter follow-up periods, but the cost per patient can still be substantial.

Phase 3 Study Costs

Phase 3 studies are the largest and most expensive phase of clinical development. A Phase 3 study cost ranged from US$11.5 million in dermatology to US$52.9 million in pain and anesthesia on average [7]. The high cost of pain and anesthesia trials reflects the difficulty of recruiting patients, the need for large sample sizes to detect modest treatment effects, and the cost of managing chronic pain conditions.

Phase 3 budgets must include the cost of multiple sites, large patient populations, long treatment and follow-up periods, and extensive data collection. The cost per patient in a 200-site, 1000-patient Phase 3 hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia study was US$89,600 per patient, with screen failures and screen failure rates identified as the main cost drivers [12]. This example demonstrates that patient selection and recruitment efficiency have direct financial consequences.

Total Research and Development Investment

The cost of a single trial is only one component of the total investment required to bring a new medicine to market. A study using publicly available data on new therapeutic agents approved by the US Food and Drug Administration between 2009 and 2018 estimated the median capitalized research and development investment at US$985.3 million and the mean at US$1,335.9 million in the base case analysis [9]. Median estimates by therapeutic area ranged from US$765.9 million for nervous system agents to US$2,771.6 million for antineoplastic and immunomodulating agents [9].

These figures include the costs of failed trials, which are a necessary part of the drug development process. Budget planners should recognize that a single trial budget is part of a larger portfolio and that the cost of failed trials must be recovered from the revenue of successful products.

Patient Recruitment Costs and Strategies

Patient recruitment is consistently identified as a major contributor to clinical trial costs. A study of centralized patient outreach recruitment metrics and cost data from eight sponsor and contract research organizations across several major therapeutic areas found that the median budget for centralized patient outreach recruitment was US$1,334,821 across 32 studies [16]. Social media, including Facebook ads, Instagram, and Google ads, was widely used across all studies, with an average allocation of 64.7% of the total centralized patient outreach recruitment budget [16].

The median centralized outreach recruitment cost per patient ranged from US$143 in vaccine studies to US$11,392 in immunology studies [16]. This wide range reflects differences in disease prevalence, patient willingness to participate, and the complexity of the recruitment strategies required.

Recruitment planning should include the following steps:

1. Estimate the number of patients needed to achieve the target enrollment, accounting for screen failures and dropout rates.
2. Identify the most effective recruitment channels for the specific therapeutic area and patient population.
3. Budget for centralized outreach strategies such as social media advertising, patient advocacy group engagement, and community outreach.
4. Track cost per patient by recruitment strategy and adjust the mix based on observed performance.
5. Plan for the cost of screening procedures for all patients who consent, including those who fail screening.

The cost of screen failures deserves particular attention. In the hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia Phase 3 trial model, screen failures and screen failure rates were the main cost drivers [12]. Strategies to improve screening and recruitment can decrease clinical trial costs, and biopharmaceutical companies and regulatory agencies should consider such strategies [12].

Clinical Procedure Costs and Protocol Design

Clinical procedure costs represent 15% to 22% of total trial expenditures across all phases, excluding site overhead and sponsor monitoring costs [7]. These costs include laboratory tests, imaging studies, biopsies, electrocardiograms, and other protocol-required procedures.

Protocol design decisions directly influence procedure costs. A protocol that requires extensive laboratory monitoring at every visit will cost more than a protocol with a leaner visit schedule. The choice of endpoints also matters. A trial that uses a surrogate endpoint requiring specialized laboratory testing will have higher procedure costs than a trial that uses a clinical endpoint requiring only routine assessments.

Budget planners should work with the protocol development team to identify every procedure required by the protocol and estimate the unit cost at each site. The cost calculation template developed for paediatric trials includes a detailed list of aspects to be considered when estimating the specific time required for measures and investigations [10]. The same approach can be applied to any therapeutic area.

The Assay Guidance Manual from the National Center for Advancing Translational Sciences provides information on the design and validation of assays used in drug development [3]. Assay development and validation costs should be included in the trial budget when the protocol requires novel or specialized laboratory tests.

Site Selection, Site Numbers, and Administrative Costs

The number of sites and the geographic distribution of sites have a direct impact on trial costs. A trial with 200 sites will have higher site activation, training, and monitoring costs than a trial with 50 sites. However, more sites may be needed to achieve enrollment targets within a reasonable timeframe.

Administrative staff costs are among the top cost drivers of clinical trial expenditures [7]. These costs include the salaries of study coordinators, data managers, regulatory specialists, and other personnel who support the trial. Site overhead costs, which cover the indirect costs of conducting research at a site, must also be included in the budget.

The study of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia Phase 3 trials modeled the fully loaded cost of a typical Phase 3 study, including both direct and indirect costs [12]. The fully loaded cost per patient of US$89,600 in a 200-site, 1000-patient study illustrates the magnitude of indirect costs when site overhead and sponsor monitoring are included.

Budget planners should obtain detailed cost estimates from each site before finalizing the budget. Site costs can vary significantly based on geographic location, institutional overhead rates, and the complexity of the procedures required. A site feasibility assessment should include a review of the site's capabilities, patient population, and historical enrollment performance.

Health Economics Analysis in Clinical Trials

Health economics analysis is increasingly integrated into clinical trial design. Cost-effectiveness analyses conducted alongside clinical trials can inform resource allocation decisions and reimbursement discussions. A review of eight randomized clinical trial-based cost-effectiveness studies of antipsychotic medications identified seven threats to validity related to measurement of costs, measurement of effectiveness, analysis of costs, measurement of sampling uncertainty, analysis of incomplete cost data, minimizing loss to follow-up, and threats to external validity [8].

The same review found that economic claims made by the authors of a number of trial-based economic evaluations were generally favorable to second-generation antipsychotics, but the methodological issues identified suggested that there was no clear evidence that atypical antipsychotics generate cost savings or are cost-effective in general use among all schizophrenia patients [8]. This finding underscores the importance of rigorous health economics methodology in trial-based economic evaluations.

Health economics analysis can also be used in the design and analysis of adaptive clinical trials [20]. Adaptive trial designs allow for modifications to the trial based on interim data, which can improve efficiency and reduce costs. However, the integration of health economics into adaptive designs requires careful planning and analysis.

The practice and policy of measuring quality of life and health economics in cancer clinical trials varies among co-operative trial groups [21]. Some groups routinely collect quality of life and economic data, while others do not. Budget planners should consider whether health economics endpoints are required for the trial's objectives and include the associated data collection and analysis costs in the budget.

Budget Planning Framework

Step 1: Define the Trial Scope

The first step in budget planning is to define the trial scope, including the therapeutic area, phase, number of patients, number of sites, and duration. The therapeutic area and phase determine the benchmark costs that should be used for planning purposes [7]. The number of patients and sites determines the scale of the trial and the associated costs.

Step 2: Identify Cost Categories

The budget should include the following cost categories:

1. Clinical procedure costs, including laboratory tests, imaging, and other protocol-required procedures.
2. Patient recruitment costs, including centralized outreach strategies and site-level recruitment activities.
3. Site costs, including site activation, overhead, and per-patient payments.
4. Administrative staff costs, including study coordinators, data managers, and regulatory specialists.
5. Sponsor monitoring costs, including site visits, data review, and quality assurance.
6. Data management and biostatistics costs.
7. Regulatory and ethics review costs.
8. Drug supply and distribution costs.
9. Health economics and quality of life data collection costs, if applicable.
10. Contingency funds for unexpected expenses.

Step 3: Estimate Costs by Category

Each cost category should be estimated using the best available data. Published benchmarks can provide a starting point, but site-specific cost estimates are essential for an accurate budget. The cost calculation template developed for paediatric trials includes a detailed list of aspects to be considered when estimating the specific time required for measures and investigations [10]. The same approach can be applied to any trial.

Step 4: Model Screen Failures and Dropouts

Screen failures and dropouts add to trial costs because the cost of screening and early follow-up is incurred for patients who do not complete the trial. The hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia Phase 3 trial model identified screen failures and screen failure rates as the main cost drivers [12]. Budget planners should model screen failure rates based on the therapeutic area and protocol design and include the cost of screening procedures for all patients who consent.

Step 5: Include Indirect Costs

Indirect costs, including site overhead and sponsor monitoring costs, are often overlooked in trial budgets. A review of 97 clinical trial reports with cost data found that general overhead was not presented in 91 of the 97 studies and that only 14 mentioned start-up costs [11]. The same review found that statements regarding cost without substantiating data are made habitually in reports of clinical trials [11]. Budget planners should include indirect costs explicitly and document the basis for each cost estimate.

Step 6: Review and Revise

The budget should be reviewed and revised as the protocol evolves and as site-specific cost estimates are obtained. A budget that is finalized before site selection is complete will likely need revision. The review process should include input from the protocol development team, the biostatistician, the data management team, and the sites.

Records and Measurements for Budget Tracking

Accurate budget tracking requires a system for recording actual expenditures against budgeted amounts. The following records should be maintained:

1. A detailed budget with line items for each cost category.
2. A tracking log for actual expenditures by cost category.
3. A patient enrollment and screen failure log.
4. A site activation and monitoring log.
5. A recruitment strategy performance log, including cost per patient by strategy.

The cost-effectiveness analysis of radiation treatment schedules using Medicare claims data illustrates the importance of accurate cost data [13]. The study found that Medicare claims data permitted estimation of cost effectiveness, but the data provided inadequate representation of results applicable to patients from the general population [13]. This limitation highlights the need for trial-specific cost data collection instead of reliance on administrative claims data alone.

The problem of representativeness of clinical trial participants also has implications for cost estimation [14]. If the trial population is not representative of the general patient population, the cost data collected in the trial may not be generalizable to real-world practice. Budget planners should consider the representativeness of the trial population when interpreting cost data.

Common Failure Patterns in Trial Budgeting

Underestimating Screen Failure Costs

Screen failures are a major cost driver in many therapeutic areas [12]. Budgets that do not explicitly account for the cost of screening procedures for patients who fail screening will be underfunded. The solution is to model screen failure rates based on the therapeutic area and protocol design and to include screening costs for all patients who consent.

Omitting Indirect Costs

General overhead and start-up costs are frequently disregarded in clinical trial reports [11]. Budgets that omit indirect costs will understate the true cost of the trial. The solution is to include site overhead and sponsor monitoring costs explicitly in the budget.

Using Benchmarks Without Adjustment

Published benchmarks provide a useful starting point, but they must be adjusted for the specific trial design, therapeutic area, and sites. A Phase 3 pain and anesthesia trial will cost more than a Phase 3 dermatology trial [7]. The solution is to use benchmarks as a reference and to build a bottom-up budget based on the specific protocol requirements.

Ignoring Recruitment Costs

Patient recruitment is a major contributor to clinical trial costs [16]. Budgets that do not include a dedicated recruitment budget will be underfunded. The solution is to plan recruitment strategies early and to track cost per patient by strategy.

Failing to Plan for Health Economics Data Collection

Health economics data collection adds to trial costs, but the costs are often not included in the budget. The practice and policy of measuring quality of life and health economics in cancer clinical trials varies among co-operative trial groups [21]. The solution is to determine whether health economics endpoints are required and to include the associated data collection and analysis costs in the budget.

Limitations of Published Cost Estimates

Published cost estimates have several limitations that budget planners should recognize. The study of clinical trial costs using data from Medidata Solutions relied on aggregate data from three proprietary databases and may not reflect the experience of all sponsors and sites [7]. The estimates of research and development investment were based on publicly available data for 63 of 355 new drugs and biologics approved by the FDA between 2009 and 2018, and the authors noted that data were missing for many products [9].

Cost estimates also vary over time due to inflation, changes in regulatory requirements, and shifts in the cost of clinical procedures and personnel. Budget planners should adjust published estimates for inflation and for the specific circumstances of their trial.

The cost-effectiveness analysis of antipsychotic medications identified threats to validity related to measurement of costs, measurement of effectiveness, analysis of costs, measurement of sampling uncertainty, analysis of incomplete cost data, minimizing loss to follow-up, and threats to external validity [8]. These threats apply to trial-based economic evaluations generally and should be considered when interpreting cost-effectiveness results.

Regulatory and Quality Context

Clinical trial conduct is governed by regulatory requirements that affect trial costs. The World Health Organization Laboratory Quality Management System Handbook provides guidance on the quality management systems needed for laboratory testing in clinical trials [1]. The World Health Organization Laboratory Biosafety Manual provides guidance on biosafety practices for laboratories handling biological materials [2]. Compliance with these standards adds to trial costs but is necessary for patient safety and data integrity.

The US Food and Drug Administration Bioanalytical Method Validation Guidance provides recommendations for the validation of bioanalytical methods used in clinical trials [4]. Bioanalytical method validation is required for pharmacokinetic and immunogenicity assays and adds to the cost of trials that include these analyses.

The NCBI Literature Resources and PubMed provide access to the biomedical literature, including studies of clinical trial costs and health economics methodology [5][6]. These resources can support evidence-based budget planning.

Professional Escalation Criteria

Budget planners should escalate concerns to senior management or the sponsor when the following conditions are present:

1. The estimated budget exceeds the available funding by more than 20%.
2. Site-specific cost estimates vary by more than 50% across sites for the same procedures.
3. Screen failure rates exceed the rates used in the budget model.
4. Recruitment costs per patient exceed the budgeted amount by more than 50%.
5. The protocol is changed in a way that materially affects the cost of clinical procedures or the number of visits.
6. Regulatory requirements change in a way that adds to the cost of the trial.

Escalation should include a revised budget and a clear explanation of the reasons for the variance.

Budget Impact Analysis and Payer Perspectives

Budget impact analysis is a tool used by payers and health systems to estimate the financial consequences of adopting a new treatment. Examples of budget impact analyses include studies of radiofrequency renal denervation for hypertension in Italy [15], venetoclax for acute myeloid leukemia in the United States [17], and semaglutide for heart failure with preserved ejection fraction and obesity in Germany [19]. These analyses estimate the costs of new treatments relative to existing options and inform coverage and reimbursement decisions.

Budget impact analysis is distinct from cost-effectiveness analysis. Cost-effectiveness analysis compares the costs and health outcomes of alternative treatments, while budget impact analysis estimates the total financial impact of adopting a new treatment over a specific time horizon. Both types of analysis are used in health technology assessment and can inform clinical trial design and pricing decisions.

The reimbursement review of seladelpar for primary biliary cholangitis in Canada illustrates the role of health technology assessment in reimbursement decisions [18]. The review considered the clinical evidence and cost-effectiveness of seladelpar relative to existing treatments and informed a recommendation to participating public drug programs [18].

Frequently Asked Questions

What is the most important cost driver in clinical trials?

Clinical procedure costs represent 15% to 22% of total trial expenditures across all phases, excluding site overhead and sponsor monitoring costs [7]. However, the most important cost driver varies by therapeutic area and phase. In hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia Phase 3 trials, screen failures and screen failure rates were the main cost drivers [12]. Patient recruitment is also a major contributor to trial costs, with a median centralized outreach recruitment budget of US$1,334,821 across six therapeutic areas [16].

How much does a Phase 3 clinical trial cost?

The average cost of a Phase 3 study ranged from US$11.5 million in dermatology to US$52.9 million in pain and anesthesia [7]. The cost per patient in a 200-site, 1000-patient hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia study was US$89,600 [12]. The total cost depends on the therapeutic area, number of patients, number of sites, and protocol complexity.

Why do clinical trial costs vary so much by therapeutic area?

Therapeutic area is an important determinant of clinical trial costs by phase [7]. Differences in disease prevalence, patient recruitment difficulty, the complexity of clinical procedures, and the cost of managing the disease all contribute to the variation. For example, pain and anesthesia trials are expensive because of the difficulty of recruiting patients and the need for large sample sizes, while dermatology trials are less expensive because of lower recruitment and procedure costs.

What is the cost of patient recruitment in clinical trials?

The median budget for centralized patient outreach recruitment was US$1,334,821 across 32 studies in six therapeutic areas [16]. The median centralized outreach recruitment cost per patient ranged from US$143 in vaccine studies to US$11,392 in immunology studies [16]. Social media advertising accounted for an average of 64.7% of the total centralized patient outreach recruitment budget [16].

How should screen failures be budgeted?

Screen failures and screen failure rates are the main cost drivers in some therapeutic areas [12]. Budget planners should model screen failure rates based on the therapeutic area and protocol design and include the cost of screening procedures for all patients who consent. The budget should include a line item for screening costs that covers both patients who enroll and patients who fail screening.

What indirect costs should be included in a clinical trial budget?

General overhead and start-up costs are frequently disregarded in clinical trial reports [11]. Indirect costs include site overhead, sponsor monitoring costs, administrative staff, and start-up costs. The fully loaded cost per patient in a hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia Phase 3 trial included both direct and indirect costs [12]. Budget planners should include indirect costs explicitly and document the basis for each cost estimate.

How is health economics analysis used in clinical trials?

Health economics analysis is used to evaluate the cost-effectiveness of treatments and to inform resource allocation decisions. Trial-based cost-effectiveness studies face threats to validity related to measurement of costs, measurement of effectiveness, analysis of costs, measurement of sampling uncertainty, analysis of incomplete cost data, minimizing loss to follow-up, and threats to external validity [8]. Health economics analysis can also be used in the design and analysis of adaptive clinical trials [20].

What is the total cost of bringing a new medicine to market?

The median capitalized research and development investment to bring a new drug to market was estimated at US$985.3 million, and the mean investment was estimated at US$1,335.9 million in the base case analysis [9]. Median estimates by therapeutic area ranged from US$765.9 million for nervous system agents to US$2,771.6 million for antineoplastic and immunomodulating agents [9]. These figures include the costs of failed trials.

Related Articles

• High-Resolution Melting Analysis (HRMA) for Rapid Genotyping of Canine Distemper Virus Strains in Clinical Samples
• Digital Droplet PCR (ddPCR) for Absolute Quantification of Swine Enteric Coronaviruses in Fecal and Oral Fluid Samples: Analytical Sensitivity and Clinical Utility
• Multiplex Real-Time RT-PCR for Differential Diagnosis of Canine Infectious Respiratory Disease Complex (CIRDC): Panel Design, Validation, and Clinical Utility
• Clinical Biochemistry and Urinalysis
• Diagnostic Cytology and Fluid Analysis

References and Further Reading

• Laboratory Quality Management System Handbook. World Health Organization.
• Laboratory Biosafety Manual. World Health Organization.
• Assay Guidance Manual. National Center for Advancing Translational Sciences.
• Bioanalytical Method Validation Guidance. U.S. Food and Drug Administration.
• NCBI Literature Resources. National Center for Biotechnology Information.
• PubMed. National Library of Medicine.
• Key cost drivers of pharmaceutical clinical trials in the United States.. Clinical trials (London, England), 2016.
• Clinical trial-based cost-effectiveness analyses of antipsychotic use.. The American journal of psychiatry, 2006.
• Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018.. JAMA, 2020.
• Joint recommendations on cost calculation and estimation in paediatric clinical trials.. German medical science : GMS e-journal, 2024.
• Interpreting cost analyses of clinical interventions.. JAMA, 1998.
• Cost Drivers of a Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Phase 3 Clinical Trial.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018.
• Feasibility of using administrative claims data for cost-effectiveness analysis of a clinical trial.. Journal of medical economics, 2008.
• The problem of representativeness of clinical trial participants: understanding the role of hidden costs.. Journal of health services research & policy, 2016.
• Cost-Effectiveness and Budget Impact Analysis of Radiofrequency Renal Denervation for Uncontrolled and Resistant Hypertension in Italy.. 2026.
• Measuring Centralized Patient Outreach Recruitment Strategies and their Costs in Clinical Trials.. 2026.
• Budget Impact of Venetoclax for Newly Diagnosed Patients with Acute Myeloid Leukemia Aged ≥ 75 Years or with Comorbidities Precluding Intensive Chemotherapy in the United States.. 2026.
• Seladelpar (Lyvdelzi): Therapeutic area: Primary biliary cholangitis: Reimbursement Review. 2026.
• Cost-Effectiveness and Budget-Impact Analysis of Semaglutide in Heart Failure with Preserved Ejection Fraction and Obesity in the German Health-Care System.. 2026.
• How can health economics be used in the design and analysis of adaptive clinical trials? A qualitative analysis. Trials, 2020.
• Practice and policy of measuring quality of life and health economics in cancer clinical trials: A survey among co-operative trial groups. Quality of Life Research, 2000.
• A systematic review of methodology in clinical trial-based health economics study with cost-effectiveness ratio for nutritional drug in T3 transfer of translational medicine. Chinese Journal of Clinical Nutrition, 2020.
• Basics of health economics for clinical trials in orthopaedic trauma. Injury, 2023.

This article is educational and does not replace institutional policy, professional advice, or applicable safety and regulatory requirements.